Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. (DWTX): 4 pipeline candidates · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.0 months
D/E 0.18 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Dogwood Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$50.1M
Cash
$13.2M
Quarterly Burn
$4.6M
Runway
9.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Dogwood Therapeutics, Inc.'s pipeline?
Dogwood Therapeutics, Inc. (DWTX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dogwood Therapeutics, Inc.'s lead drug candidate?
Dogwood Therapeutics, Inc.'s most advanced tracked candidate is halneuron (Phase 2) for Chemotherapy Induced Neuropathic Pain.
What is Dogwood Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dogwood Therapeutics, Inc. has approximately 9.0 months of cash runway.
What is Dogwood Therapeutics, Inc.'s market capitalization?
Dogwood Therapeutics, Inc.'s market capitalization is approximately $50.1M.
Who is the CEO of Dogwood Therapeutics, Inc.?
Mr. Gregory Duncan is the chief executive officer of Dogwood Therapeutics, Inc. (DWTX).
Get the full picture on Dogwood Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.